Examining the Evolving Utility of FDG-PET/CT in Breast Cancer Recurrence

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2022 Feb 4

PMID 35117953

Authors

Navid Djassemi

Shilpa Rampey

Juhi Motiani

Affiliations

Soon will be listed here.

Abstract

Many studies have demonstrated the utility of fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) scan in evaluating breast cancer recurrence in subsets of patients based on age, histological subtype and cancer stage to guide response to conventional chemoradiation guidelines during treatment of metastatic breast cancer disease. This literature review focuses on the breakthrough of FDG-PET/CT imaging within the paradigm of breast cancer oncology centered toward improving risk stratification and prognostication of disease relapse based on cancer molecular phenotypes, tumor markers, early metabolic activity and response to neoadjuvant chemotherapy (NAC). The authors consider the rapid shift toward biomarker based molecular tracers to quantify treatment response and pathologic complete response with more recent imaging modalities such as dedicated breast positron emission tomography (dbPET), and the advantages afforded by this multisystem approach.

Citing Articles

PET Molecular Imaging in Breast Cancer: Current Applications and Future Perspectives.

Katal S, McKay M, Taubman K J Clin Med. 2024; 13(12).

PMID: 38929989 PMC: 11205053. DOI: 10.3390/jcm13123459.

Radiogenomic analysis of primary breast cancer reveals [18F]-fluorodeoxglucose dynamic flux-constants are positively associated with immune pathways and outperform static uptake measures in associating with glucose metabolism.

Ralli G, Carter R, McGowan D, Cheng W, Liu D, Teoh E Breast Cancer Res. 2022; 24(1):34.

PMID: 35581637 PMC: 9115966. DOI: 10.1186/s13058-022-01529-9.

References

Xiao Y, Wang L, Jiang X, She W, He L, Hu G . Diagnostic efficacy of 18F-FDG-PET or PET/CT in breast cancer with suspected recurrence: a systematic review and meta-analysis. Nucl Med Commun. 2016; 37(11):1180-8. DOI: 10.1097/MNM.0000000000000573. View

Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P . "Tumour marker guided" salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother. 2003; 57(10):452-9. DOI: 10.1016/j.biopha.2003.09.004. View

Keam B, Im S, Koh Y, Han S, Oh D, Cho N . Early metabolic response using FDG PET/CT and molecular phenotypes of breast cancer treated with neoadjuvant chemotherapy. BMC Cancer. 2011; 11:452. PMC: 3224348. DOI: 10.1186/1471-2407-11-452. View

Katzenellenbogen J, Welch M, Dehdashti F . The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer. Anticancer Res. 1997; 17(3B):1573-6. View

Elder E, Kennedy C, Gluch L, Carmalt H, Janu N, Joseph M . Patterns of breast cancer relapse. Eur J Surg Oncol. 2006; 32(9):922-7. DOI: 10.1016/j.ejso.2006.06.001. View

van Kruchten M, de Vries E, Brown M, de Vries E, Glaudemans A, Dierckx R . PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013; 14(11):e465-e475. DOI: 10.1016/S1470-2045(13)70292-4. View

Evangelista L, Cervino A, Ghiotto C, Al-Nahhas A, Rubello D, Muzzio P . Tumor marker-guided PET in breast cancer patients-a recipe for a perfect wedding: a systematic literature review and meta-analysis. Clin Nucl Med. 2012; 37(5):467-74. DOI: 10.1097/RLU.0b013e31824850b0. View

Garcia Vicente A, Soriano Castrejon A, Cruz Mora M, Gonzalez Ageitos A, Mar Munoz Sanchez M, Leon Martin A . Semi-quantitative lymph node assessment of (18)F-FDG PET/CT in locally advanced breast cancer: correlation with biological prognostic factors. Eur J Nucl Med Mol Imaging. 2012; 40(1):72-9. DOI: 10.1007/s00259-012-2244-3. View

Heudel P, Cimarelli S, Montella A, Bouteille C, Mognetti T . Value of PET-FDG in primary breast cancer based on histopathological and immunohistochemical prognostic factors. Int J Clin Oncol. 2010; 15(6):588-93. DOI: 10.1007/s10147-010-0120-3. View

10.

Soret M, Bacharach S, Buvat I . Partial-volume effect in PET tumor imaging. J Nucl Med. 2007; 48(6):932-45. DOI: 10.2967/jnumed.106.035774. View

11.

You J, Cline K, Gu C, Pritchard K, Dayes I, Gulenchyn K . (18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancer. Br J Cancer. 2015; 112(11):1737-43. PMC: 4647251. DOI: 10.1038/bjc.2015.151. View

12.

Higuchi T, Fujimoto Y, Ozawa H, Bun A, Fukui R, Miyagawa Y . Significance of Metabolic Tumor Volume at Baseline and Reduction of Mean Standardized Uptake Value in F-FDG-PET/CT Imaging for Predicting Pathological Complete Response in Breast Cancers Treated with Preoperative Chemotherapy. Ann Surg Oncol. 2019; 26(7):2175-2183. PMC: 6545174. DOI: 10.1245/s10434-019-07325-8. View

13.

Koolen B, Pengel K, Wesseling J, Vogel W, Vrancken Peeters M, Vincent A . FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer. Breast. 2013; 22(5):691-7. DOI: 10.1016/j.breast.2012.12.020. View

14.

Zucchini G, Quercia S, Zamagni C, Santini D, Taffurelli M, Fanti S . Potential utility of early metabolic response by 18F-2-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in a selected group of breast cancer patients receiving preoperative chemotherapy. Eur J Cancer. 2013; 49(7):1539-45. DOI: 10.1016/j.ejca.2012.12.024. View

15.

Evangelista L, Baretta Z, Vinante L, Cervino A, Gregianin M, Ghiotto C . Could the serial determination of Ca15.3 serum improve the diagnostic accuracy of PET/CT?: results from small population with previous breast cancer. Ann Nucl Med. 2011; 25(7):469-77. DOI: 10.1007/s12149-011-0488-9. View

16.

Ulaner G, Hyman D, Ross D, Corben A, Chandarlapaty S, Goldfarb S . Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med. 2016; 57(10):1523-1528. PMC: 5050126. DOI: 10.2967/jnumed.115.172031. View

17.

Kostakoglu L, Agress Jr H, Goldsmith S . Clinical role of FDG PET in evaluation of cancer patients. Radiographics. 2003; 23(2):315-40; quiz 533. DOI: 10.1148/rg.232025705. View

18.

Jones E, Ray K, Li W, Chien A, Mukhtar R, Esserman L . Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol. NPJ Breast Cancer. 2019; 5:12. PMC: 6467896. DOI: 10.1038/s41523-019-0107-9. View

19.

Schwarz-Dose J, Untch M, Tiling R, Sassen S, Mahner S, Kahlert S . Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose. J Clin Oncol. 2008; 27(4):535-41. DOI: 10.1200/JCO.2008.17.2650. View

20.

Garcia Garcia-Esquinas M, Garcia-Saenz J, Arrazola Garcia J, Enrique Fuentes Ferrer M, Furio V, Rodriguez Rey C . 18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors. Q J Nucl Med Mol Imaging. 2013; 58(1):66-73. View